Original ArticleSunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study
Under an Elsevier user license
open archive
Key Words
Non–small-cell lung cancer
Sunitinib
Erlotinib
Safety
Pharmacokinetics
Cited by (0)
Disclosure: Tiziana Usari is an employee of Pfizer, the manufacturer of sunitinib. Ana Ruiz-Garcia, Lesley Tye, and Richard Chao are all employees of Pfizer and hold stock in the company. The other authors declare no conflicts of interest.
Copyright © 2012 International Association for the Study of Lung Cancer. All rights reserved.